(2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2S,5R,6R)-6-[[3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid | 910292-83-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2S,5R,6R)-6-[[3-(2-chlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
• CAS: 910292-83-0
• 化学式: C35H37ClN6O10S2
• 分子量: 801.3
• InChiKey: YTPMUOBEKFIBJT-TWZKVBNYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.57
• 重原子数：
  54
• 可旋转键数：
  8
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  296
• 氢给体数：
  6
• 氢受体数：
  14

文献信息

• Stable oral pharmaceutical formulation containing an anti-infective agent and a microorganism
  申请人：Cadila Pharmaceuticals Ltd.

  公开号：US20020025309A1

  公开（公告）日：2002-02-28

  A stable fixed dose oral pharmaceutical formulation is provided. The formulation contains at least one anti-infective agent and at least one susceptible microorganism as active ingredients. At least one of the active ingredients is coated to provide a protective barrier around the active ingredient, the active ingredients being contained in a single pharmaceutical formulation. The formulation may be a tablet, a capsule, or a powder which may be made into a stable liquid. The protective barrier protectis the susceptible micro-organism from the effect of the anti-infective agent to maintain the susceptible micro-organism in a viable form for a period of at least three months. The anti-infective agent can be an antibiotic such as an amoxycillin and the microorganism can be Lactobacillus acidophilus.

  本研究提供了一种稳定的固定剂量口服药物制剂。该制剂含有至少一种抗感染剂和至少一种易感微生物作为活性成分。至少一种活性成分被包衣，以在活性成分周围提供保护屏障，活性成分包含在一个药物制剂中。制剂可以是片剂、胶囊或粉末，也可以制成稳定的液体。保护屏障可保护易感微生物免受抗感染剂的影响，使易感微生物在至少三个月的时间内保持活力。抗感染剂可以是抗生素，如阿莫西林，微生物可以是 嗜酸乳杆菌。
• Bioavailability enhancing activity of Carum carvi extracts and fractions thereof
  申请人：Qazi Nabi Ghulam

  公开号：US20050214390A1

  公开（公告）日：2005-09-29

  The present invention relates to the use of extracts of Carum carvi as bioenhancers, either alone or in combination with piperine or Zinzeber officinale extract to improve the bioavailability of a wide variety of drugs.
• Bioavailability enhancing activity of carum carvi extracts and fractions thereof
  申请人：Qazi Nabi Ghulam

  公开号：US20060257505A1

  公开（公告）日：2006-11-16

  The present invention relates to the use of extracts of Carum carvi as bioenhancers, either alone or in combination with piperine or Zinzeber officinale extract to improve the bioavailability of a wide variety of drugs.
• US6306391B1
  申请人：——

  公开号：US6306391B1

  公开（公告）日：2001-10-23